Auna Announces 3Q24 Financial Results Adjusted EBITDA increases 23% YoY FXN, maintaining strong growth Leverage ratio decreases 0.4x to 3.7x Luxembourg

Announces 3Q24 Financial Results

Adjusted EBITDA increases 23%

YoY FXN, maintaining strong growth

Leverage ratio decreases 0.4x

Luxembourg, November 19, 2024 - Auna (NYSE:

AUNA) ("Auna" or the "Company"), a leading healthcare platform in Latin America with operations in Mexico,

Peru and Colombia, today announced unaudited financial results for the third quarter ended September 30, 2024 ("third quarter 2024"

or "3Q24"). Financial results are expressed in Peruvian Soles ("S/" or PEN") and are presented in accordance

with International Financial Reporting Standards ("IFRS"), unless otherwise noted.

3Q24 Consolidated Highlights

from Auna's Executive Chairman and President

We delivered a strong quarter. We increased capacity

utilization across the regional network which allowed us to achieve record sales. In addition, Adjusted EBITDA reached historical highs

in Mexico and Peru which enabled Auna to reduce our leverage ratio to 3.7x Net Debt-to-Adjusted EBITDA.

In Mexico, the implementation of the AunaWay -

fostering a culture of patient-centered care, high medical resolution resulting from productive engagement with Auna's physician

and nursing communities, and standardization at scale - continues to yield improved financial results. Our unique approach improves utilization

rates and revenues through increased physician productivity and a greater mix of high-complexity services. We anticipate this positive

trend will continue and accelerate during 2025.

The early results of our OncoMexico pilot program

are encouraging, as we leverage over 35 years of experience providing integrated oncological services in Peru. We will continue the pilot

through the remainder of 2024 and into early 2025, focusing on testing commercial, clinical, and risk-underwriting processes in preparation

for the launch of OncoMexico by integrating our insurance business into our healthcare platform in Monterrey. The launch will initially target the

B2B segment, with plans to scale to the B2C segment later.

In Peru, where our integrated model is most

developed, we continue to deliver high performance levels, driven by sustained plan membership demand and ticket growth, as well as scale

productivity gains and an ongoing shift toward higher-complexity procedures across our network in the country.

In Colombia which is an important contributor of

scale and excellence in clinical practices across Auna, we will continue to regionalize these advantages. We remain optimistic about its

medium and long-term prospects. However, we are tempering our growth in the short term. While our cash conversion cycle is managed with

rigor, the regulator intervention in some payors, including Nueva EPS, requires a cautious stance in relation to our account receivables

growth and related provisions.

With the aforementioned strong performance, during

the quarter, we reduced Auna's leverage, marking the eighth consecutive quarter of a lower Net Debt-to-Adjusted EBITDA ratio, which

improved to 3.7x at the end of the quarter, keeping us on track to achieve our medium-term target of less than 3.0x.

In addition, as we continue to further strengthen

Auna's capabilities, we recently made a series of adjustments to our organization and team structure.

In summary, we remain optimistic about Auna's

near and long-term growth prospects, particularly regarding our progress in implementing the AunaWay in Mexico and our ongoing expansion

in Peru. Although we remain optimistic in Colombia that the tensions between the authorities and payors, and between payors and providers,

like ourselves, will be reduced in the medium term, we are managing the situation with prudence and vigilance. Thus, in the near term,

in Colombia, we will favor cash flow over growth.

The fragmented and underserved healthcare market

in Spanish-speaking Latin America remains highly attractive. Through our distinctive operating model and scalable regional platform, we

will continue to innovate, modernize, and expand access to integrated healthcare across the region, always with a sharp focus on providing

high value to our patients, their families, Auna staff, and our shareholders.

Overview of 3Q24 Consolidated Results

Revenues increased 11% YoY to

S/1,127 million, or 13% FXN, as a result of Auna's improving sales mix, with revenues increasing 16% in local currency ("L.C.")

in Mexico, 13% in Peru and 11% in Colombia.

In Mexico, the results reflect improvements

in productivity and service mix through the implementation of the AunaWay. During the quarter, Auna's Peruvian operation continued

to outperform, demonstrating the strength of the Company's vertically integrated business model when operating at scale. Colombia

kept pace with sustained

demand for oncology services, consistent

with Auna's ongoing focus to high-complexity care in the country.

Adjusted EBITDA increased 18%

YoY, or 23% FXN, to S/250 million, with the corresponding margin expanding 1.4 p.p. to 22.1% on solid revenue growth and increasing efficiencies

across local and regional levels as the Company continues to capture synergies and streamline processes. Operating profit increased 53%

YoY and included a one-time S/44 million reversal of the holdback from the acquisition of OCA in Mexico; excluding this reversal, the

operating profit would have increased 24% YoY. Consolidated Adjusted EBITDA was impacted by provisions for impairment losses of S/16 million

on account receivables in Colombia; excluding these reserves, consolidated Adjusted EBITDA would have been S/265 million, a 30% FXN growth

Net finance costs were S/103 million

in 3Q24 versus S/172 million in 3Q23. When excluding FX effects, net interest expenses would have been S/132 million, a decrease of S/23

million or 15% versus 3Q23. These FX effects include a non-cash accounting FX benefit of S/28 million, corresponding mainly to the appreciation

of the Peruvian Sol to the Mexican Peso.

Net Income was S/101 million in

3Q24, compared to Net Income of S/8 million in 2Q24 and Net Loss of S/18 million in 3Q23. On a per-share basis, Auna reported Net Income

of S/1.32 based on a weighted average number of basic and diluted shares of 74,175,144.

Adjusted Net Income was S/75 million

in 3Q24, versus S/13 million in 2Q24 and a loss of S/17 million in 3Q23. On a per-share basis, Auna reported Adjusted Net Income of S/0.98

based on a weighted average number of basic and diluted shares of 74,175,144.

Business performance

(Explanations of variances are

Auna s Healthcare Services and AunaSeguros

operations in Mexico accounted for 28% of consolidated revenues and 46% of Adjusted EBITDA.

(Figures in millions of Soles

and millions of US Dollars, unless expressed otherwise)

Revenue in Mexico increased 16% year-over-year,

driven by a rise in surgical procedures, hospitalizations and ICU therapy services, along with higher average tickets related to such

During the third quarter, total capacity utilization

was 43.4%, an increase of 1.3 p.p. versus 2Q24, while operating capacity utilization reached 65.3%, increasing 2.0 p.p. versus 2Q24.

The implementation of the AunaWay continued to

produce positive results in Monterrey, as the Company remains focused on driving accelerated growth in Mexico, largely through increased

doctor productivity and payor referrals, as well as higher average ticket through an increased mix of high-complexity services.

Segment Adjusted EBITDA

Although gross margin decreased slightly, due to

investments in new compensation programs for doctors, Adjusted EBITDA in Mexico grew 34% YoY, with an increase in margin. Further, the

increase in Adjusted EBITDA was achieved despite YoY increases in fixed costs and SG&A related to building Auna's regional capabilities

PERU OPERATIONS: HEALTHCARE

SERVICES PERU AND ONCOSALUD PERU

Auna s Healthcare Services and OncoSalud

Peru (Auna's Healthcare plans business in Peru) accounted for 40% of consolidated revenues and 39% of Adjusted EBITDA.

(Figures in millions of Soles

and millions of US Dollars, unless expressed otherwise)

Total revenue from Peru increased 13% year-over-year